Vertex gets Priority Review voucher from Symdeko approval

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said it received a Priority Review voucher on Jan. 29 from FDA based on the February 2018 approval of Symdeko tezacaftor/ivacaftor to treat cystic fibrosis i...